Engflag

Deka

Quick links to important sections

Deka

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deka

Property Description
Active Ingredients Dexbrompheniramine, Dextromethorphan, Guaifenesin, Pseudoephedrine
Form Oral Preparation (e.g., tablet, liquid)
Pharmacological Class Multi-component therapeutic agent
Common Use Symptomatic relief of respiratory discomfort
Origin Synthetic and Semi-synthetic

What Type of Medicine is Deka?

Deka is formally classified as a fixed-dose combination product, an oral preparation that integrates four distinct active pharmaceutical ingredients. Its identity is defined by its complex internal structure, positioning it as a multi-component therapeutic agent for upper respiratory discomfort. The preparation combines the functional activities of an Antihistamine, an Antitussive, an Expectorant, and a Decongestant into one formulation. The broad use of these combinations is supported by clinical databases for the relief of combined symptoms of the common cold. This indicates the drug's purpose is to simultaneously manage the multiple discomforts that often occur together. Deka, as a multi-ingredient product, is clinically recognized for addressing the need for integrated relief, particularly where symptoms like nasal congestion and a persistent cough coincide.

Deka's Composition: A System of Four Active Ingredients

The essential components that define Deka are Dexbrompheniramine, Dextromethorphan, Guaifenesin, and Pseudoephedrine, all compounds of synthetic or semi-synthetic origin. These ingredients are formulated using stable salts, such as Dextromethorphan Hbr and Pseudoephedrine Hcl, to optimize delivery within the oral preparation. This combination strategy is a long-standing method in pharmacology to provide systemic relief, with each ingredient targeting a different physiological system involved in respiratory distress. A distinguishing feature of Deka is the strategic co-inclusion of both an antihistamine (Dexbrompheniramine) and a high-potency decongestant (Pseudoephedrine), which targets both allergic reactions and sinus congestion simultaneously.

The General Purpose of Deka: Integrated Symptomatic Relief

The general purpose of Deka is to achieve integrated symptomatic relief across various physiological pathways associated with cold and allergy symptoms. The combination enables the product to reduce allergic activity and alleviate nasal congestion concurrently. This multi-symptom management capability is Deka's defining functional characteristic, enabling it to provide comprehensive relief from the spectrum of discomforts, including cough, congestion, and nasal secretions. A typical use scenario for Deka involves alleviating the disruptive symptoms of the common cold or seasonal allergies that impact general well-being.

What side effects are possible with Deka?

Possible Side Effects and Safety Information

The officially documented adverse effects of Deka, a multi-component therapeutic agent, are classified by the physiological systems they affect. Regulatory labeling identifies effects on the Central Nervous System (CNS), Cardiovascular System, and Gastrointestinal System as key domains.

Commonly Documented Adverse Reactions

Adverse effects most frequently reported in regulatory labeling include drowsiness or sedation, and dryness of the mouth, nose, and throat. Other common effects documented are dizziness, nervousness, sleeplessness (insomnia), and constipation.

Serious Adverse Reactions

The label documents the potential for rare, but serious, adverse reactions. These include severe cardiovascular events such as cardiac arrhythmias and hypertension, as well as severe CNS effects like convulsions and hallucinations. Rare hematologic effects, such as agranulocytosis and hemolytic anemia, are also noted in official documents.

Safety Constraints and Specific Populations

The safety profile establishes critical restrictions for use. Deka is strictly contraindicated for use in patients taking, or within 14 days of stopping, Monoamine Oxidase Inhibitors (MAOIs), due to the risk of serious drug interactions. Furthermore, it is not to be used in patients with severe hypertension or severe coronary artery disease. Regulatory documents advise against use in newborns, premature infants, and nursing mothers. For individuals over 60, adverse reactions such as confusion and dizziness may be more likely.

Overdose and Emergency Response

Overdose and When to Seek Help

The name “Deka” is associated with various medical products. When reviewing authoritative sources for general overdose information, there is no single established drug monograph for a substance named Deka. Instead, the name is used in relation to: 1) a medical device, such as an Infusion System (regulated by the FDA), and 2) some compounded or multi-ingredient oral liquids containing other agents like Dextromethorphan/Dexamethasone, which carry known overdose risks.

Since the medical device itself is not a substance that can be overdosed on, its regulatory materials focus on safe use and contraindications. The official labeling for the DEKA Infusion System indicates that it is not intended for delivery of high-alert medications, blood, or blood products. It is also contraindicated for use with pediatric patients and adults with certain critical conditions, such as Congestive Heart Failure or Acute Respiratory Distress Syndrome, to prevent complications from improper infusion.

Required Emergency Action

If Deka refers to a product containing active ingredients like Dextromethorphan (often used in cough medicines), an overdose is a medical emergency. Symptoms may include:

  • Severe drowsiness or confusion
  • Blurred vision or hallucinations
  • Nausea, vomiting, or muscle twitches
  • Changes in heart rate or blood pressure
  • Seizures or unresponsiveness

In the event of a suspected overdose of any medication or product, immediate medical attention is required. If the person has collapsed, is having trouble breathing, or cannot be awakened, call emergency services immediately. Contacting a poison control center is also a standard procedural instruction for guidance in poisoning emergencies.

Therapeutic Uses of Deka

What Deka Treats: Main Uses and Benefits

The medication Deka is commonly used to help with conditions that involve significant tissue loss, bone weakness, or chronic fatigue. Its therapeutic benefits are primarily supportive and contribute to general well-being. It is applied when appropriate across chronic conditions where the body struggles to maintain mass or function.

Deka is relevant for easing symptoms across three main domains: symptoms of severe weakness and unintentional body wasting due to long-term illness, issues of reduced bone density such as in certain cases of osteoporosis, and anemia-related fatigue notably associated with chronic kidney disease. This supportive role contributes to improved day-to-day comfort during symptomatic periods.

“The medication is applied in clinical settings that involve acute or unstable symptom patterns.”

Quick Fact: Relief for Chronic Fatigue

Deka is commonly used to help with the pronounced weakness and low energy that interfere with daily functioning when these symptoms are caused by certain types of anemia. It supports patients during these symptomatic periods by assisting with maintaining functional stability.

Regulatory References

  1. National Library of Medicine's DailyMed drug information

Eligibility and Restrictions for Use

Deca-Durabolin (nandrolone decanoate) is a prescription medicine with specific regulatory requirements defining who is eligible to use it and who must not.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated and must not be used by several patient groups, including:

  • Men with known or suspected carcinoma of the prostate or carcinoma of the male breast, as this type of medication can accelerate tumor growth.
  • Women who are pregnant or who may become pregnant, as it carries a risk of virilisation (masculinization) of a female fetus. It is also not recommended for women who are breastfeeding.
  • Patients with a known hypersensitivity to the active substance or any excipients (e.g., those with a peanut or soya allergy).

Age-Related and Condition-Specific Restrictions

Population Group Eligibility Status (Regulatory)
Infants (< 3 years) Contraindicated (Due to benzyl alcohol excipient)
Children/Adolescents Safety and efficacy not adequately determined; requires close monitoring for bone maturation
Cardiac, Renal, or Hepatic Disease Use with great caution; requires immediate discontinuation if complications (e.g., edema) occur

Eligibility for use is conditional and requires close medical supervision in patients with conditions like heart failure, kidney disease, liver disease, hypertension, or epilepsy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Deka is established by the combined regulatory information for its four active components. This profile is structured around defined prohibitions and documented changes in drug exposure or activity with other substances.

Contraindicated Combinations and Timing

Co-administration of Deka with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated according to regulatory labeling. A mandatory 14-day separation period is required; Deka must not be administered within 14 days of discontinuing or starting therapy with an MAOI. This strict timing rule is in place to prevent severe, officially documented adverse reactions related to both the sympathomimetic and antitussive components.

Pharmacokinetic and Pharmacodynamic Interactions

A pharmacokinetic interaction is documented with Strong CYP2D6 Inhibitors (such as quinidine and fluoxetine). These medicines reduce the metabolic clearance of the Dextromethorphan component, resulting in increased systemic exposure and elevated plasma concentrations, including the area under the curve ( AUC).

Pharmacodynamic interactions involve additive effects on the central nervous system (CNS). Co-administration with other CNS Depressants (e.g., sedatives, tranquilizers) or Alcohol is noted to enhance drowsiness and impairment. Furthermore, combining Deka with other Serotonergic Agents increases the regulatory risk of serotonergic reinforcement. Using Deka with other Sympathomimetic Amines or certain herbal products (e.g., Ephedra, Ginseng) may also result in additive systemic effects.

Mechanism of Action

Modulating Vascular Tone and H1 Receptor Activity

This domain explains how Pseudoephedrine activates alpha1-adrenergic receptors to constrict nasal blood vessels, while Dexbrompheniramine blocks peripheral Histamine H1 receptors. This combined action reduces vascular flow and permeability, resulting in a physical decrease in mucosal swelling and glandular secretion.

Central Regulation of the Cough Reflex Arc

The antitussive mechanism is driven by Dextromethorphan's agonism at central Sigma-1 (sigma1) receptors in the brainstem's Medullary Cough Center. This action modulates neural signaling to increase the excitability threshold, meaning stronger input is required to trigger a cough, thereby influencing the frequency of the reflex.

Modulation of Tracheobronchial Secretion Dynamics

The expectorant mechanism utilizes Guaifenesin to stimulate vagal afferent nerves in the stomach, initiating a gastro-pulmonary reflex. This reflex increases the flow of less viscous fluid from the tracheobronchial glands, impacting clearance mechanisms by modifying secretion properties to facilitate mobilization.

Dosage and Administration Information

The medicine Deka is officially used exclusively via deep intramuscular injection, as it is formulated as a sterile oleaginous solution and not intended for oral intake. The administration route and required setting (clinical supervision) define a highly controlled use environment.

Dosing regimens are designed around the long-acting properties of the medication. For general anabolic or tissue-wasting processes, the standard adult dose typically ranges from 50 mg to 100 mg per administration. Higher doses may apply for specific conditions, such as for men with renal anemia, where the official labeled dosage can be 100 mg to 200 mg. All dosage amounts and schedules are detailed in the official prescribing information.

The core principle of Deka's use is intermittent frequency. It is not administered daily; the injection is generally scheduled every three to four weeks. For younger patients, specifically those aged 2 to 13 years, the labeled dose is a lower range, often 25 mg to 50 mg, administered on the same multi-weekly schedule.

This medicine is explicitly defined as an adjunctive therapy. Its effectiveness is tied directly to the context of use, requiring the patient to have sufficient intake of calories and protein to support the intended physiological effect. Treatment is administered in time-bound courses, typically restricted to a duration of up to 12 weeks of continuous use before reassessment, establishing a critical parameter for the overall treatment protocol.

Recent Clinical Evidence

Deka: Recent Clinical Evidence

Evidence Summary for Acute Low Back Pain

Research has primarily focused on the use of this substance for acute, non-specific low back pain.

Studies evaluated whether the substance is associated with improvement in the symptoms of acute, non-specific low back pain. This reported effect persisted over the 7-day treatment course assessed in the trial.

The majority of research examined pain intensity and functional limitation scores. Secondary endpoints evaluated in the trials included the need for rescue medication and global assessment by the study participant.

Combination Therapy Studies

Research has explored whether combining this substance with other pain relievers or muscle relaxants is associated with different outcomes.

One trial examined whether the combination with a common muscle relaxant was associated with greater reported pain reduction than either substance alone. The study assessed whether this combination was associated with changes in mobility in patients over a two-week period.

Safety and Tolerability Profile

The substance's tolerability was assessed in studies. Research examined potential associations with symptoms. Side effects reported were primarily assessed as mild and temporary.

The most common side effects reported in the clinical trials included mild stomach discomfort, nausea, and headache. These side effects were reported in various demographic groups studied.

Studies evaluated doses within a specific range. Trials primarily assessed treatment initiation using lower dose ranges.

Frequently Asked Questions (FAQ)

Common questions about Deka (FAQ)

Q: I am taking a strong CYP2D6 inhibitor; will this affect the concentration of Deka in my body?

A: Official prescribing information notes a potential pharmacokinetic interaction between Deka and strong CYP2D6 inhibitors. These types of medicines may reduce the breakdown of the Dextromethorphan component of Deka. This is associated with increased concentrations of Dextromethorphan in the system, including a higher area under the curve (AUC), which reflects overall exposure to the substance.

Q: For what duration, in weeks, is a typical course of treatment with Deka usually restricted?

A: Regulatory guidance defines Deka treatment in time-bound courses. Continuous use is typically restricted to a duration of up to 12 weeks, after which a reassessment is generally required by regulatory protocol. This establishes a critical parameter for the overall treatment period.

Q: Is Deka used alone, or does it need to be combined with other therapies, like diet?

A: Deka is explicitly defined as an adjunctive therapy, meaning it is intended to be used alongside other treatments. Its effectiveness is tied to the patient's nutritional status, requiring the consideration of sufficient intake of calories and protein to support the intended physiological effect. Therefore, it is not used in isolation and is intended to be supported by sufficient nutritional intake.

Q: How does Guaifenesin in Deka help with coughing?

A: The Guaifenesin component of Deka is classified as an expectorant. According to official drug information, expectorants work by thinning and loosening phlegm or mucus in the respiratory system. This action is intended to help make coughs more productive, which assists in clearing the airways of bothersome secretions.

Q: How does Deka's combination of ingredients work to relieve cold symptoms?

A: Deka is a multi-component therapeutic agent formulated for the management of cold symptoms by offering integrated symptomatic relief. The product combines four active ingredients, each targeting a different bodily mechanism. These components work together to help raise the threshold required to trigger a cough, assist in thinning respiratory secretions, block allergic response receptors, and relieve nasal congestion.

How should Deka be stored and disposed of?

How to Store and Dispose of Deka (Nandrolone Decanoate Injection)

Official regulatory guidelines define mandatory storage and handling conditions for Deka to ensure its stability.

Storage Requirements

Condition Regulatory Requirement
Temperature Store below 25°C (or 15 C to 30 C); Do not refrigerate or freeze.
Protection Keep the product in the original outer carton to protect from light.
Child Safety Store out of the sight and reach of children.

Handling and Disposal

The ampoules or syringes are designated for single use only. Any unused solution must be immediately discarded after the container is opened. The disposal of the expired or unused medicine and any waste materials must be carried out in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Deka found in:

A-Z Index: